Table F- 6Sitagliptin compared with active therapy, as add-on to active therapy

Domains pertaining to strength of evidenceMagnitude of effectStrength of evidence
Number of Studies; # of SubjectsRisk of Bias (Design/Quality)ConsistencyDirectnessPrecisionSummary Effect Size (95% Confidence Interval)High, Moderate, Low, Insufficient
HbA1c for studies comparing sitagliptin to glipizide (add on to metformin)
1; 1172Medium
RCT/Fair
Unknown/NAIndirectPreciseSimilar reduction (between group difference −0.05%)Low
HbA1c for studies comparing sitagliptin to rosiglitazone (add on to metformin)
2; 442Medium
RCTs/Fair
ConsistentIndirectPreciseNo significant differenceModerate
HbA1c for studies comparing sitagliptin to metformin (add on to pioglitazone)
1; 151Medium
RCT/Fair
Unknown/NAIndirectPreciseSimilar reduction (between group difference 0.1 %, P=NR)Low
Weight change for studies comparing sitagliptin to glipizide (add on to metformin)
1; 1172Medium
RCT/Fair
Unknown/NAIndirectPreciseGreater weight loss with sita (−1.5 kg) compared to weight gain with glipizide (+1.1 kg)Low
Weight change for studies comparing sitagliptin to rosiglitazone (add on to metformin)
1; 273Medium
RCT/Fair
Unknown/NAIndirectPreciseGreater weight loss with sita (−0.4 kg) compared to weight gain with rosiglitazone (+1.5 kg)Low
Weight change for studies comparing sitagliptin to metformin (add on to pioglitazone)
1; 151Medium
RCT/Fair
Unknown/NAIndirectPreciseGreater weight loss with metformin (−2,8 kg) compared with sitagliptin (−1.6 kg)Low

From: Appendix F, Strength of evidence

Cover of Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations
Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations: Final Original Report [Internet].
Jonas D, Van Scoyoc E, Gerrald K, et al.
Portland (OR): Oregon Health & Science University; 2011 Feb.
Copyright © 2011, Oregon Health & Science University.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.